NeuroMetrix (NASDAQ:NURO) Releases Earnings Results

NeuroMetrix (NASDAQ:NURO) released its quarterly earnings results on Tuesday. The medical device company reported ($0.75) EPS for the quarter, RTT News reports. The company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. During the same quarter in the previous year, the business earned ($1.66) earnings per share.

NeuroMetrix Trading Up 1.7 %

NASDAQ NURO traded up $0.06 during mid-day trading on Wednesday, reaching $3.61. 10,833 shares of the company’s stock traded hands, compared to its average volume of 26,234. The company has a market cap of $7.33 million, a price-to-earnings ratio of -0.65 and a beta of 2.29. The company has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $3.88. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research note on Monday. They set a “sell” rating on the stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.